Abstract The objective of this multicenter study was to compare the clinical efficacy, safety, and acceptability of Easyhaler s and Turbuhaler s for the delivery of budesonide 200 mg/dose twice daily in steroid-na|« ve asthmatic patients. Three hundred and twenty-six newly diagnosed, steroid-na|« ve adult patients with mild-to-moderate asthma were recruited into this randomized, double-blind, double-dummy, parallel-group study, comprising a 2-week run-in period and 8 weeks of treatment.Patients received budesonide inhalation powder 400 mg/day either via Easyhaler s (n = 159) or via Turbuhaler s (n = 167), plus salbutamolinhalation powder (100 mg/dose) via Easyhaler s as rescue therapy.The study was completed by 292 patients:143 in the Easyhaler s group and149 in theTurbuhaler s group.The primary outcome variable, mean morning peak expiratory flow (PEF), improved significantly and almost similarly by 36.3 and 30.6 l/min, respectively, from run-in to weeks 728. At weeks 728, the mean (SE) difference in morning PEF between the two treatments was 7.1 (9.4) l/min (90% CI from À8.4 to 22.6) on per protocol analysis, which was withinthe definedlimits for therapeutic equivalence. There were no significant differences between treatments in terms of secondary efficacy variables or adverse events. 
INTRODUCTION
Current national and international guidelines for the treatment of patients with asthma recommend the early use of regular anti-in£ammatory therapy with inhaled corticosteroids. These agents have potent local activity: they decrease the accumulation and activation of in£am-matory cells in the asthmatic lung (1) , inhibit the release of in£ammatory mediators from e¡ector cells (2) , and upregulate beta 2 -receptor function (3) . As a result, they decrease microvascular permeability and mucus formation (4, 5) .
Clinical studies have provided extensive evidence that, irrespective of preparation, inhaled corticosteroids have minimal systemic e¡ects at doses up to 400 mg/day in children and up to 800 mg/day in adults (6) . The most common adverse drug reactions of inhaled corticosteroids are dysphonia and oral candidiasis (7) . Budesonide is a non-halogenated glucocorticosteroid derivative and is widely documented in the treatment of bronchial asthma (8) .
It is generally acknowledged that the inhaler is a key element in determining the e¡ectiveness of asthma therapy (9) . The earliest form of inhaler was the pressurized metered dose inhaler (PMDI), which remains widely used in asthma management (10) . However, many patients have di⁄culty using this device correctly (11) because of di⁄culty in co-ordinating drug release and inspiration (12) . In addition, pMDIs contain lubricants that may irritate the bronchial membrane, resulting in paradoxical bronchoconstriction (13) . Furthermore, the most commonly used propellant (chloro£uorocarbon (CFC)) has been implicated in damage to the ozone layer, hence CFC-containing MDIs will be banned in the near future.
In order to overcome these problems, breath-actuated powder inhalers were developed. One of the ¢rst multidose powder inhalers to become available wasTurbuhaler s (AstraZeneca, Sweden), which is documented for the delivery of budesonide in asthma patients as Pulmicort s Turbuhaler s (14^17). The environmental problems caused by CFC gases in pMDIs are circumvented by replacing those with alternative propellant, hydro£uoroalkane (HFA).
Easyhaler s is a new-generation, breath-actuated multidose powder inhaler developed by Orion Pharma. It has been shown to be safe and e¡ective for the delivery of salbutamol (18) and BDP (beclomethasone dipropionate) (19) 20) . Additional advantages of Easyhaler s include a dose counter, high dosing accuracy, insensitivity of ¢ne particle dose to inspiratory £ow rate, and ease of use (20) .
Easyhaler s and Turbuhaler s have been shown to deliver an equivalent ¢ne particle dose in vitro (21) , with a comparable in vivo lung deposition of Tc-labeled budesonide (22) .The present study was undertaken to compare the clinical e⁄cacy, safety, patient acceptability and tolerability of Easyhaler s and Turbuhaler s for the delivery of budesonide 200 mg/dose twice daily in steroid-na|« ve asthmatic patients.
MATERIALS AND METHODS

Patients
Adult asthmatic out-patients who had been diagnosed with bronchial asthma no more than 2 years previously were recruited into the study from 30 centers in Germany. Inclusion criteria were: age 18^70 years; non-smokers for at least 6 months prior to entry (maximum smoking history of one pack per day for 5 years); a forced expiratory volume in 1s (FEV 1 ) 60^90% of the predicted value measured within 4 weeks before or during the ¢rst visit; additionally, at least one of the following criteria 4 weeks before study entry or during the ¢rst visit:
(a) At least 15% increase in FEV 1 Exclusion criteria were: hypersensitivity to budesonide or lactose; any exacerbation of asthma or a respiratory infection during the preceding 4 weeks; hospitalization due to asthma during the previous 12 months; treatment with inhaled or systemic corticosteroids, sodium cromoglycate or nedocromil within 12 weeks before the ¢rst visit or for more than 30 days per year during the previous 5 years; manifest heart condition (NYHA Class II^IV); severe hepatic or renal disease; inadequately controlled hyperthyroidism; chronic bronchitis; diabetes mellitus (type I or II); any clinically signi¢cant deviation in safety laboratory parameters. Women were excluded if they were pregnant or breastfeeding or, if fertile, without reliable contraception. All patients who had participated in this or any other clinical trial within 8 weeks prior to study entry were also excluded. The appearance and weight of placebo was indistinguishable from the active treatment. Patients were instructed to rinse their mouth with water and spit it out after inhalation of each drug. The patients were trained to use both inhalers properly according to manufacturer's instructions.The inhaler technique was also checked during the control visits, which took place at 2-week (visits 1^4) and 4 -week (visit 5) intervals.
Study design and treatments
Salbutamol Easyhaler s could be used as rescue medication during the treatment period but preferably not during the 6 h prior to home PEF measurements or follow-up visits to the clinic for spirometry. Patients were also permitted to take a 1-week course of an oral corticosteroid if needed, but any further use resulted in withdrawal from the study.
All study documents were reviewed and approved by the Ethics Committee of the LandesÌrztekammer Bran-denburg, Germany. All patients were required to give written informed consent and the study was conducted according to the principles of the current revision of the Declaration of Helsinki (24) .
Outcome variables
The primary e⁄cacy variable was morning PEF measured at home. Daily morning (0600^0800 hours) and evening (1900^2200 hours) PEF was measured by the patient at home using a standard Vitalograph Peak Flow Meter (Vitalograph, Cat. No. 43.000G, Hamburg). Three successive exhalations were recorded and the best value was used for the ¢nal analysis.Mean PEF values were calculated for the run-in period and for treatment weeks12 , 3^4 and 7^8. Secondary e⁄cacy variables consisted of evening PEF measured at home; FEV 1 and FVC measured at follow-up visits; number of salbutamol inhalations per day during the treatment period; severity scores for asthma symptoms during the day and night; visual analog scale (VAS) scores for e⁄cacy, as determined by the patients and the investigators; and diurnal PEF variability.
The intensity of asthma symptoms (dyspnea, wheeze and cough) was scored daily by the patients and entered onto their diary cards, where 0 = no symptoms,1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Patients were asked to specify whether the symptoms occurred during the day or night or early morning.
Both patients and investigators evaluated the e⁄cacy of the treatment with a 100 mm VAS, ranging from 'not e⁄cient' (0 mm) to 'very e⁄cient' (100 mm). These evaluations were performed after the run-in period and after 8 weeks of treatment.
Patients were asked to record the occurrence of any adverse event into the diary. In addition, the investigator inquired on each visit whether patient had had any untoward medical events since last visit. The investigators performed a visual examination for oropharyngeal candidiasis at each follow-up visit. Morning (0700^0900 hours) serum cortisol measurements were performed before and after the treatment period to evaluate the possible e¡ect of budesonide on the HPA axis.
Patient acceptability of the devices was determined after 4 weeks of treatment using a questionnaire consisting of 10 questions, and a VAS, ranging from 'very poor' (0 mm) to 'very good' (100 mm).
Statistical analysis
The overall hypothesis tested in the study was therapeutic equivalence of Giona For the primary e⁄cacy variable (morning PEF measurements), data were analyzed on both an intentionto-treat (ITT) and a per protocol (PP) basis. Secondary e⁄cacy variable data were analyzed only on an ITT basis. Data from all patients entered into the study were analyzed for safety and acceptability. 
BUDESONIDE EASYHALER s AND PULMICORT TURBUHALER s IN STEROID-NAIº VE ASTHMATICS
Therapeutic equivalence was analyzed using analysis of covariance (ANCOVA). Improvement in the Easyhaler s group was analyzed using analysis of variance (ANOVA). Spirometry values were analyzed with a repeated measurements ANCOVA model, while the number of salbutamol inhalations per day, intensity scores for asthma symptoms,VAS scores for e⁄cacy and diurnal PEF variation were analyzed as change from run-in to treatment weeks 5^8. VAS scores for device acceptability were compared using the Wilcoxon signed rank test.
Safety analyses included morning serum cortisol using the ANCOVA model, and adverse events, which were classi¢ed by System Organ Class and by preferred term according to the WHO coding system. Oropharyngeal candidiasis was analyzed descriptively.
RESULTS
Patients
A total of 326 patients were recruited into the study from 30 
E⁄cacy
According to both the PP and ITTanalyses, mean morning PEF improved signi¢cantly from baseline (run-in) to weeks 7^8 with both preparations, with a mean (SD) increase of 36.3 (6.6) l/min in the Easyhaler s group and 30.6 (5.7) l/min in the Turbuhaler s group on PP analysis (Fig. 2, Table 3 ). At weeks 7^8, the mean (SE) di¡erence in morning PEF between the two treatments was 7.2 (9.4) l/min (90% CI from À8.4 to 22.6) on PP analysis and 7.0 (9.0) l/min (90% CI from À7.9 to 21.9) on ITT analysis, which was within the de¢ned limits for therapeutic equivalence.The e¡ect of sympathomimetic use on treatment di¡erence was analyzed separately by excluding the patients who had used the rescue medication regularly. Use of rescue medication decreased during the study in both treatment groups. In the Easyhaler s group, the mean (SD) number of salbutamol inhalations per day decreased from1.8 (2.2) during the run-in period to 0.7 (1.3) during treatment weeks 5^8 (Po0.001). In the Turbuhaler s group, the corresponding ¢gures were 1.5 (2.2) and 0.6 (1.0) (Po0.001), respectively.
The incidence of asthma symptoms was higher during the run-in period than during the treatment period and was similar in both treatment groups (between treatments, weeks 5^8: day symptoms P=0.83, night symptoms P=0.74) ( Table 5 ). Mean night-time symptom scores were lower than mean day-time symptom scores in both groups. There were also no statistically signi¢-cant di¡erences between the treatments in terms of e⁄-cacy based on VAS scores by investigator (P=0.61) or patient (P=0.58), which improved during the course of the study in both groups. Mean (SD) VAS e⁄cacy scores, as assessed by patient, increased by 24.4 (28.0) mm in the 
Acceptability
The mean (SD) VAS score for device acceptability was signi¢cantly higher for Easyhaler s than for Turbuhaler (Fig. 3) . In particular, patients using Easyhaler s found it easier to know when the drug had been received, and how much drug remained in the device. Furthermore, 63.8% patients said they would have chosen Easyhaler s compared with 12.4% who preferred Turbuhaler s and 22.8% who expressed no preference.
Safety
Adverse events that were considered possibly or probably related to study treatment occurred in 3.1% of Easyhaler s patients during both the ¢rst and the second half of the treatment period. In the Turbuhaler s group, 4.8% of patients experienced such events during the ¢rst half of treatment and 2.4% during the second half of treatment. Overall, 12 adverse drug reactions (ADRs) were reported in the Easyhaler s group and 16 in the Turbuhaler s group. Most of these were mild or moderate in nature. Dysphonia (3 and 4 events, respectively) and pharyngitis (4 and 5 events, respectively) were the most common reported ADRs.
Four patients withdrew from the study as a result of adverse events: one in the Easyhaler s group (irritation of the oral mucosa and throat) and three in theTurbuhaler s group (bacterial bronchitis; dyspnea and cough; and deterioration of asthma).
Only two SAEs occurred during the study, neither of which was considered related to study treatment.These consisted of one neoplasm (cervical carcinoma) in the Easyhaler s group and one respiratory system disorder (hospitalization because of dyspnoea and urinary tract infection) in theTurbuhaler s group. In the Easyhaler s group mean (SD) morning serum cortisol value was 424 (219) nmol/l after run-in, and slightly higher at visit 8 (443 [191] . Firstly, since inhaled corticosteroids may take days or weeks to exert their maximal e¡ect, the recommended minimum duration for this type of study is 4 weeks (26) . Hence, in the present study an 8 -week treatment period was selected in order to obtain a reliable assessment of the e⁄cacy, safety and acceptability of the devices under investigation. In addition, the dosage of budesonide used in this study (400 mg/day) is low compared with the average starting dose in adults (27, 28) and should be in the steep part of the budesonide dose^response curve (7), thus, enhancing the reliability of comparison between the two preparations investigated. The inclusion of a separate placebo control group was considered to be unethical in this population of newly diagnosed, untreated asthmatic patients. Joyce et al. studied the placebo e¡ect in a meta-analysis of 33 asthma drug therapy trials (29) . According to their observations, a mean absolute decrease of 2.24 l/min in PEF was observed among placebo groups, which supports the rationale for not including a placebo group in our study.
DISCUSSION
During the trial, the primary e⁄cacy variable and all secondary e⁄cacy variables improved clearly during treatment and to a similar extent in both groups. An improvement in PEF of similar magnitude has been reported in previous studies with corticosteroids in steroid-na|« ve asthmatic patients (15, 19) .
The safety and tolerability of the two preparations was good, and was comparable between the two treatment groups. The frequencies of adverse events (whether considered potentially drug-related or not) were also similar with both treatments, with no signi¢-cant e¡ect on the HPA axis. Although morning serum cortisol is not an ideal method for assessing such an effect, because of large diurnal variation, a single blood sample is the only practical method for determination of serum cortisol in a large, multicenter study of this type.
Tests (20) . The questionnaire also revealed that a majority of patients found it easier to know when the drug had been received with Easyhaler s (69.3%), compared withTurbuhaler s (2.1%).This ¢nding is likely to re£ect an additional bene¢t of incorporating a small amount (8 mg) of lactose to the budesonide dry powder, which is used to ensure a high level of dose reproducibility (20) .The amount of lactose is su⁄cient for the patient to detect, but below the level likely to cause a reaction in lactose intolerant patients (30) .
CONCLUSIONS
The results of this study indicate that Giona s (budesonide) Easyhaler s is as e¡ective as Pulmicort s Turbuhaler s when equal daily doses of budesonide are delivered to steroid-na|« ve asthmatic patients. The mean improvement in morning the primary e⁄cacy variable (PEF) seen in both treatment groups was statistically signi¢-cant. There were no signi¢cant di¡erences between the treatment groups in terms of any of the secondary e⁄-cacy variables. Similarly, there were no clinically signi¢-cant di¡erences in terms of adverse events between the study groups, and these were mostly mild or moderate in nature. Neither treatment suppressed the HPA axis, as determined by morning serum cortisol values. Both VAS testing and the use of a questionnaire demonstrated better patient acceptability of Easyhaler s compared with Turbuhaler s . In addition, the majority of patients said that they would choose Easyhaler s .
